Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.

ABSTRACT:

Importance

Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.

Objective

To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.

Design, setting, and participants

This comparative effectiveness study using tar

SUBMITTER: Shin H 

PROVIDER: S-EPMC11877166 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature